First, the phase 3 trial of Moderna’s norovirus vaccine had to endure a clinical hold. | First, the phase 3 trial of ...

Vaxart secures major Dynavax deal, extending cash runway to 2027. Get Q3 earnings insights, clinical progress, and outlook on innovative oral vaccines.

CAMBRIDGE, MA / ACCESSWIRE / September 30, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that the first participant in the U.S. has been dosed in the Nova 301 Trial, a pivotal Phase 3 randomized ...

SOUTH SAN FRANCISCO, Calif., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant ...

Moderna’s nearly $20 billion cash hoard has dwindled to a single-digit stash. Following a series of setbacks for the biotech, ...

- Second-generation constructs induce robust increases in fecal IgA, which was shown to be correlated with protection against infection in the company’s previous Phase 2b challenge study - SOUTH SAN ...

Outbreaks of norovirus, an extremely contagious stomach bug, can spread quickly. “‘Tis the season for germs,” said Dr.

Hundreds of Boston residents and some Boston University students who ended up in the emergency room with the norovirus this winter may take comfort in a recent research breakthrough that may help ...

Entered into an exclusive license agreement with Dynavax for the Company’s COVID-19 oral pill vaccine candidate for potential cumulative proceeds ...

Vaxart Inc (VXRT) announces a major partnership with Dynavax and reports significant revenue growth, while navigating market ...